Characteristics of lipid metabolism and the cardiovascular system in glycogenosis types I and III


Cite item

Full Text

Abstract

Glycogen storage disease (GSD) is an inherited metabolic disorder characterized by early childhood lipid metabolic disturbances with potentially proatherogenic effects. The review outlines the characteristics of impaired lipid composition and other changes in the cardiovascular system in GSD types I and III. It analyzes the factors enabling and inhibiting the development of atherosclerosis in patients with GSD. The review describes the paradox of vascular resistance to the development of early atherosclerosis despite the proatherogenic composition of lipids in the patients of this group.

About the authors

N V Polenova

ФГБУН «ФИЦ питания и биотехнологии»

Москва, Россия

T V Strokova

ФГБУН «ФИЦ питания и биотехнологии»

Москва, Россия

A V Starodubova

ФГБУН «ФИЦ питания и биотехнологии»

Москва, Россия

References

  1. Сурков А.Н. Гликогеновая болезнь у детей: современные представления (часть I). Вопросысовременнойпедиатрии. 2012;11(2):30-42. https://doi.org/10.15690/vsp.v11i2.208
  2. Постановление Правительства Российской Федерации от 26.04.2012 №403 «О порядке ведения Федерального регистра лиц, страдающих жизнеугрожающими и хроническими прогрессирующими редкими (орфанными) заболеваниями, приводящими к сокращению продолжительности жизни граждан или их инвалидности, и его регионального сегмента». http://base.garant.ru/70168888/
  3. Суспицын Е.Н., Стрекалов Д.Л., Янус Г.А.. Генетические заболевания. Краткий справочник. СПб.; 2015.
  4. Ozen H. Glycogen storage diseases: new perspectives. World J. Gastroenterol. 2007;13(18):2541-2553. https://doi.org/10.3748/wjg.v13.i18.2541
  5. Дворяковская Г.М., Уварова Е.В., Дворяковский И.В.. Оценка эффективности лечения гликогенозов по данным ультразвуковой диагностики. Ультразвуковая и функциональная диагностика. 2007;3:51-60.
  6. Краснов М.В., Кириллов А.Г., Краснов В.М. Наследственные болезни у детей. Практическая медицина. 2009;7(39):22-30. http://pmarchive.ru/nasledstvennye-bolezni-u-detej/
  7. Bhattacharya K. Investigation and management of the hepatic glycogen storage diseases. TransnarionalPediatrics. 2015;4(3):240-248. https://doi.org/10.3978/j.issn.2224-4336.2015.04.07
  8. Строкова Т.В., Мачулан И.В., Кутырева Е.Н. Клинико-лабораторные проявления гликогеновой болезни I типа у детей раннего возраста. Доктор.ру. 2013;9(87).
  9. Ефременко И.И. Наследственные болезни человека: справочник. Витебск: УО «ВГУ им. П.М. Машерова»; 2012.
  10. Kalkan S, Coker M, Sözmen E. A monocentric pilot study of an antioxidative defense and hsCRP in pediatric patients with glycogen storage disease type IA and III. Nutririon. Metabolism and cardiovascular disease. 2009;19(6):383-390. https://doi.org/10.1016/j.numecd.2008.09.005
  11. Kasakara CS, Cinasal G, Hasanoglu A. Endogenous glucose production from infancy to adulthood: a non-linear regression model. Arch Dis Child. 2014;1098-1102. https://doi.org/10.1016/S0300-595X(83)80051-6
  12. Priya S. Kishnani MD, Stephanie L. Austin MS, MA, Jose E. Abdenur MD Diagnosis and management of glycogen storage disease type I: a practice .guideline of the American College of Medical Genetics and Genomics Genetics in Medicine. 2014. https://doi.org/10.1038/gim.2014.128
  13. Dietrich Matern, Hans Hermann Seydewitz, Deeksha Bali, Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. European Journal of Pediatrics. 2002;161(1):S10-S19. https://doi.org/10.1007/s00431-002-0998-5
  14. Shin YS. Glycogen storage disease: clinical, biochemical, and molecular heterogeneity. SeminPediatrNeurol. 2006;13(2):115-120. https://doi.org/10.1007/s11845-013-0939-5
  15. Уварова Е.В. Течение гликогеновой болезни печени у детей в условиях комплексной терапии: Автореф. дис. … канд. мед. наук. М.; 2005. http://www.dissercat.com/content/techenie-glikogenovoi-bolezni-pecheni-u-detei-v-usloviyakh-kompleksnoi-terapii-0
  16. Баранов А.А. Федеральные клинические рекомендации по оказанию медицинской помощи детям с печеночной формой гликогеновой болезни Утверждены на XVIII Конгрессе педиатров России «Актуальные проблемы педиатрии» 14 февраля 2015 г. и на VII Съезде Российского общества медицинских генетиков 19-23 мая 2015 г. http://www.pediatr-russia.ru/sites/default/files/file/kr_pfgb.pdf
  17. Talente G, Coleman R, Alter C et al. Glycocen storage disease in adults. Intern Med. 1994;120:218. http://annals.org/aim/article/707084/glycogen-storage-disease-adults
  18. Austin L, Proia A, Spencer-Manzon MJ. Cardiac Pathology in Glycogen Storage Disease Type III JIMD Reports — Case and Research Reports, 2012;6:65-72. https://doi.org/10.1007/8904_2011_118
  19. Senocak F, Sarclar M, Ozkutlu S. Echocardiographic findings in some metabolic storage diseases. Jpn Heart J. 1994;35(5):635-643. https://doi.org/10.1016/j.cld.2004.06.009
  20. Goeppert B, Lindner M, Vogel MN et al. Noncompoaction myocardium in association with type Ib glycogen storage disease. Pathol Res. 2012;208(10):620-622. https://doi.org/10.1016/j.prp.2012.06.007
  21. Humbert M, Labrune Ph, Simonneau G. Severe pulmonary arterial hypertension in type 1 glycogen storage disease. European journal of pediatrics. 2002;161:93-96. https://doi.org/10.1007/s00431-002-1012-y
  22. Humbert M, Labrune P, Sitbon O. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. European respiratory journal. 2002;20:59-65. https://doi.org/10.1183/09031936.02.00258702
  23. Terry GJ, Derks C, Rijn M. Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions. J Inherit Metab Dis. 2015;38:537-543. https://doi.org/10.1007/s10545-015-9811-2
  24. Каганов Б.С. Детская гепатология. М.: Издательство «Династия»; 2009.
  25. Rake JP, Visser G, Labrune P et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002;161:S20-S34. https://doi.org/10.1007/s00431-002-0999-4
  26. Greenea H, Swifta L, Howard R. Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease. The Journal of Pediatrics. 1991;119(3):398-403. https://doi.org/10.1016/S0022-3476(05)82052-9
  27. Fernandes J, Alaupovic P, Wit J. Gastric drip feeding in patients with glycogen storage disease type I: its effects on growth and plasma lipids and apolipoproteins. Pediatr Res. 1989;25:327-331. https://doi.org/10.1203/00006450-198904000-00002
  28. Rifkind B, Segal P. The Lipid Research Clinics Program Epidemiology Committee Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. American Journal of Epidemiology. 1990;131:32-47. https://doi.org/10.1001/jama.1983.03340140039025
  29. Bandsma R., Prinsen B. Increased de novo Lipogenesis and Delayed Conversion of Large VLDL into Intermediate Density Lipoprotein Particles Contribute to Hyperlipidemia in Glycogen Storage Disease Type 1a. Pediatric Research. 2008;63(6):702-707. https://doi.org/10.1203/PDR.0b013e31816c9013
  30. Sever S, Weinstein DA, Wolfsdorf J. Glycogen Storage Disease Type Ia: Linkage of Glucose, Glycogen, Lactic Acid, Triglyceride, and Uric Acid Metabolism. JClinLipidol. 2012;6(6):2-6. https://doi.org/10.1016/j.jacl.2012.08.005
  31. Строгий В.В. Нарушения липидного обмена у детей и подростков. Минск: БГМУ; 2009.
  32. Carvalho PM, Silva NJ, Dias PG. Glycogen Storage Disease type 1a — a secondary cause for hyperlipidemia: report of five cases. Journal of Diabetes and Metabolic Disoders. 2013;12-25. https://doi.org/10.1186/2251-6581-12-25
  33. Bernier AV, Sentner CP, Correia CE. Hyperlipidemia in glycogen storage disease type III: Effect of age and metabolic control. J Inherit Metab Dis. 2008;31(6):729. https://doi.org/10.1007/s10545-008-0919-5
  34. XH Li, QM Gong, Y Ling. Inherent lipid metabolic dysfunction in glycogen storage disease IIIa. Biochem Biophys Res Commun. 20145;455(1-2):90-97. https://doi.org/10.1016/j.bbrc.2014.10.096
  35. Vivatrat N, Barshop BA, Jones KL. 2009. Severe hypertriglyceridemia and recurrent pancreatitis in a girl with type Ia glycogen storage disease and type III hyperlipoproteinemia. Am J Med Genet Part A. 149A:2557-2559. https://doi.org/10.1002/ajmg.a.33046
  36. Шульпекова Ю.О. Патогенетическое значение липидов при неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012;1:45-56.
  37. Лаврова А.Е., Варначева Л.Н., Шабунина Е.И., Колесов С.А., Коркоташвили Л.В., Быстранова Д.В., Дмитриева Г.В. Особенности нарушений липидного обмена у детей с гепатобилиарной патологией. Вопросы cовременной педиатрии. 2014;13(2):107-111. https://doi.org/10.15690/vsp.v13i2.980
  38. Zhang P-Y, Xu X, Li X-C. Cardiovascular diseases: oxidative damage and antioxidant protection. Eur Rev Med Pharmacol Sci. 2014;18(20):3091-3096. https://doi.org/10.1113/expphysiol.1997.sp004024
  39. Wittensteina B, Kleina M, Finckha B. Plasma antioxidants in pediatric patients with glycogen storage disease, diabetes mellitus, and hypercholesterolemia. Free Radical Biology and Medicine. 2002; 33(1):103-110. https://doi.org/10.1016/S0891-5849(02)00863-8
  40. Bernier AV, Correia CE, Haller MJ. Vascular Dysfunction in Glycogen Storage Disease Type I. Journal of pediatric. 2009;154(4);588-591. https://doi.org/10.1016/j.jpeds.2008.10.048
  41. Ubels FL, Rake JP, Slaets JP et al. Is Glycogen storage disease Ia associated with atherosclerosis? Eur J Pediatr. 2002;161(1):62-62. https://doi.org/10.1007/BF02679997
  42. Robert HJ. Bandsma Jan-Peter Rake Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with Glycogen Storage Disease type 1a Adapted from: Journal of Pediatrics. 2002;140:256-260. https://doi.org/10.1067/mpd.2002.121382
  43. Goulart JM, Yoo JY, Kirchoff-Torres KF et al. Ischemic stroke in an adult with glycogen storage disease type I. J Clin Neurosci. 2010;17:1467-1469. https://doi.org/10.1016/j.jocn.2010.03.026
  44. Boudjemline AM, Petit F, Buron A. Glycogen storage disease type I (GSD I). AtlasGenetCytogenetOncolHaematol. 2012;16(11):860-863. https://doi.org/10.4267/2042/48238
  45. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза Российские рекомендации V пересмотр. Национальное общество по изучению атеросклероза (НОА), Российское кардиологическое общество (РКО) Российское общество кардиосоматической реабилитации и вторичной профилактики (РосОКР). Москва 2012 год. http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf
  46. Yekeler E, Dursun M, Emeksiz E. Prediction of premature atherosclerosis by endothelial dysfunction and increased intima-media thickness in glycogen storage disease types Ia and III. The Turkish Journal of Pediatrics. 2007;49:115-129. http://search.proquest.com/openview/b9174aa2ad8da3597ef4803aa87fd642/1?pq-origsite=gscholar
  47. Rake F, Slaets J. Hyperlipidaemia and atherosclerosis in Glycogen Storage Disease type I. Eur J Pediatr. 2002;160:62-64. http://www.rug.nl/research/portal/files/3014583/c5.pdf
  48. Muhlhausen C, Schneppenheim R, Budde U, et al. Decreased plasma concentration of von Willebrand factor antigen in patients with glycogen storage disease type Ia. J Inherit Metab Dis. 2005;28:945-950. https://doi.org/10.1007/s10545-005-0184-9
  49. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126. https://doi.org/10.1056/NEJM199901143400207
  50. Tamaki M, Tamura Y, Ogihara T. Lack of evident atherosclerosis despite multiple risk factors in glycogen storage disease type 1a with hyperadiponectinemia. Metabolism clinical and experimental. 2007; 10:1402-1404. https://doi.org/10.1016/j.metabol.2007.06.002
  51. Lee PJ, Celermajer, DS, Robinson et al. Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a. Atherosclerosis. 1994;110:95-100. https://doi.org/10.1016/0021-9150(94)90072-8

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies